Antibacterial Drug Development: A New Approach Is Needed for the Field to Survive and Thrive

Antibiotics
M Courtney SafirChristopher M Rubino

Abstract

It is often said that the marketplace for new antibiotics is broken. This notion is supported by the observation that many recently-approved antibiotics to treat drug-resistant bacteria have failed commercially in a spectacular fashion. Today, companies with peak market-cap values in excess of USD 500 million to 1 billion prior to product launch regularly sell for pennies on the dollar a few years after market introduction. It is possible, however, that the market is not as broken as we perceive. That is, in the collective mind of the clinician, recently-approved antibiotics may be too-poorly differentiated to justify their broad use and inordinate cost relative to those already existing. Perhaps we in the antibacterial drug development field must change our way of thinking if we are to survive and thrive. Rather than reflexively developing new β-lactam-β-lactamase inhibitor combinations for every new enzyme that evades our current inhibitors, we should focus discovery and development efforts on agents that revolutionize how we potentiate antibiotics. To this end, there has been renewed interest in phage therapies, virulence inhibitors, bacterial growth rate modulators, monoclonal antibodies, and other approaches to augment ant...Continue Reading

References

Jan 19, 2010·Current Opinion in Microbiology·Christian Baron
Jan 1, 2009·Current Pharmaceutical Biotechnology·Jason J Gill, Paul Hyman
Sep 3, 2010·Trends in Biotechnology·Mzia Kutateladze, Revaz Adamia
Mar 4, 2011·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Jenny Fernebro
Jan 17, 2012·Seminars in Cancer Biology·Casey W ShuptrineLouis M Weiner
Aug 25, 2015·Current Opinion in Microbiology·Antonio DiGiandomenico, Bret R Sellman
Nov 9, 2016·Antimicrobial Agents and Chemotherapy·Paul G AmbroseSujata M Bhavnani
Nov 30, 2016·Current Microbiology·Agata Anna CisekZbigniew Wyżewski
Jan 26, 2017·The New England Journal of Medicine·Mark H WilcoxUNKNOWN MODIFY I and MODIFY II Investigators
Nov 29, 2017·Antimicrobial Agents and Chemotherapy·Shankaramurthy ChannabasappaBharathi Sriram
Jan 31, 2018·Antimicrobial Agents and Chemotherapy·Paul G AmbroseChristopher M Rubino
Nov 23, 2018·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Jason P BurnhamMarin H Kollef
Nov 30, 2018·Frontiers in Pharmacology·Luca FalzoneMassimo Libra
Feb 15, 2019·Cell Host & Microbe·Kaitlyn E KortrightPaul E Turner
Apr 5, 2020·Antibiotics·Daniel V Zurawski, Molly K McLendon
Apr 10, 2020·The Journal of Clinical Investigation·Vance G FowlerCara Cassino
May 1, 2020·Proceedings of the National Academy of Sciences of the United States of America·Xiaoling XuHaiming Wei
Jun 3, 2020·European Journal of Internal Medicine·Corrado CampochiaroAlberto Zangrillo

❮ Previous
Next ❯

Citations

Oct 31, 2020·Folia Microbiologica·M Łusiak-SzelachowskaAndrzej Górski

❮ Previous
Next ❯

Software Mentioned

CARB

Related Concepts

Related Feeds

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Related Papers

Gastroenterology Nursing : the Official Journal of the Society of Gastroenterology Nurses and Associates
Marilyn Schaffner
Ohio Nurses Review
Jeanette K Chambers
© 2021 Meta ULC. All rights reserved